Last reviewed · How we verify

NCT04853654

Investigation of the Effects of Selective Exercise Training in Multiple Sclerosis

Completed NA Last updated 13 January 2022
What this trial tests

NA trial testing exercise in Multiple Sclerosis in 33 participants. Completed in 15 June 2020.

Timeline
15 September 2018
Primary endpoint
15 April 2020
15 June 2020

Quick facts

Lead sponsorSanko University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment33
Start date15 September 2018
Primary completion15 April 2020
Estimated completion15 June 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Sanko University

Who can join

Adults 18 to 50, any sex, with Multiple Sclerosis or Exercise. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Selective exercise programs specific to muscle groups, with the workload to be done in line with the muscle's own structure, can enable more strength to be released with less fatigue in MS, and this increase in strength can increase balance and functional activities. to determine the effects of type training (selective exercise training), eccentric and concentric training on function, balance, fatigue and muscle architecture.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of exercise

Trials testing the same drug.

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Sanko University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04853654.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing